Vicore PharmaVCRE
那斯達克 · USD
12.50
+0.50
(+4.17%)
收盤 08/22 03:45 (UTC+8)
08/22 03:45 (UTC+8)
Vicore PharmaVCRE
12.50
+0.50
(+4.17%)
財務數據
損益表
- 0.05
- 0.01
- 0.02
- 0.00
- 0.01
- -
- -82.52
- 95.74
- -
- 43.68
- 營業收入(億)
- 季增長率(%)
單位：美元千元
2026/Q1 | 2025/Q4 | 2025/Q2 | 2025/Q1 | 2024/Q4 | |
營業收入淨額 | 602 | 419 | 1,746 | 892 | 5,103 |
營業成本 | - | - | - | - | - |
營業毛利 | 602 | 419 | 1,746 | 892 | 5,103 |
營業費用 | 124,447 | 134,126 | 112,917 | 92,437 | 99,192 |
研發費用 | 102,595 | 113,038 | 99,419 | 78,728 | 81,597 |
推銷及管理費用 | 21,512 | 22,063 | 14,077 | 14,126 | 16,964 |
非經常性項目費用 | - | - | - | - | - |
其他營業費用 | 340 | -975 | -579 | -417 | 631 |
營業利益 | -123,845 | -133,707 | -111,171 | -91,545 | -94,089 |
其他收入及費用 | - | - | - | - | - |
利息費用 | 643 | 8,547 | 14,500 | 26,405 | 1 |
稅前純益 | -108,530 | -137,103 | -115,363 | -111,535 | -84,075 |
所得稅 | 86 | - | - | - | - |
稅後純益 | -108,616 | -137,103 | -115,363 | -111,535 | -84,075 |
基本每股稅後盈餘(元) | -3.90 | -5.40 | -4.90 | -4.80 | - |
稀釋每股稅後盈餘(元) | -3.90 | -5.40 | -4.90 | -4.80 | - |
基本平均股數(千股) | 28152.00 | 25575.00 | 23458.00 | 23457.00 | - |
稀釋平均股數(千股) | 28152.00 | 25575.00 | 23458.00 | 23457.00 | - |
還原基本每股稅後盈餘(元) | -3.90 | -5.40 | -4.90 | -4.80 | - |
還原稀釋每股稅後盈餘(元) | -3.90 | -5.40 | -4.90 | -4.80 | - |
還原基本平均股數(千股) | 28,152 | 25,575 | 23,458 | 23,457 | - |
還原稀釋平均股數(千股) | 28,152 | 25,575 | 23,458 | 23,457 | - |
EBITDA(千元) | -107,887 | -128,556 | -100,863 | -85,130 | -84,074 |